University of California-aligned Mission Bay Capital's third fund attracted UC Investments, Eli Lilly, Astellas Pharma and Wilson Sonsini Goodrich & Rosati as limited partners.
Mission Bay Capital, the venture capital arm of University of California-aligned commercialisation office California Institute for Quantitative Biosciences (QB3), has raised $60m for its third life sciences fund from partners including UC Investments.
Mission Bay also secured contributions from chemicals and pharmaceuticals firm Zambon’s Zcube unit in addition to drug makers Eli Lilly and Astellas Pharma, with the latter contributing through subsidiary Astellas Venture Management.
Private equity firm Banyan Pacific Capital, venture capital firm Mayfield and law firm…
